北京若生智能科技有限公司
Drug Database
TR

transdermal DDS (Latitude / transdermal DDS, 3M / TDDS)

✓ Approved

3M Pharmaceuticals · 小分子 · 小分子

什么是 transdermal DDS？

transdermal DDS 是一种小分子，由3M Pharmaceuticals研发。该药已获批，用于治疗相关适应症，给药途径：Transdermal。

药物档案

商品名Latitude, transdermal DDS, 3M, TDDS
公司3M Pharmaceuticals
药物类别小分子
给药途径Transdermal
状态Approved
来源： ClinicalTrials.gov, 3M Pharmaceuticals

治疗适应症

transdermal DDS 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedChemical record (New York, N.Y.)2026-09-10

From Barrier Disruption to Precision Skin Interface Engineering: Next-Generation Transdermal Drug Delivery.

Zhou Cong-Zheng CZ, Lin Xin-Yu XY, Yu Shou-Shan SS, Qiao Sheng-Lin SL

Transdermal drug delivery (TDD) is reemerging as a clinically attractive route for noninvasive therapy, driven by the growing demand for alternatives to repeated injection and by the rapid development of materials capable of regulating transport across the skin. By avoiding gastrointestinal degradation and hepatic first-pass metabolism, TDD can provide prolonged drug exposure, reduce peak-to-trough fluctuations in plasma concentration, and improve adherence in long-term treatment. Its broader implementation, however, is still constrained by the exceptional barrier function of the stratum corneum, which severely limits the passive transport of hydrophilic molecules, charged species, and macromolecular therapeutics. In this review, we critically discuss the structural basis of the skin barrier and summarize the evolution of TDD strategies from conventional chemical permeation enhancement and device-assisted physical disruption to nanocarrier-mediated, biomimetic, and intelligent bio-delivery systems. Particular emphasis is placed on the mechanistic logic that connects carrier composition, interfacial interactions, skin microenvironment remodeling, and therapeutic performance. Representative examples are analyzed to highlight both opportunities and translational bottlenecks. Finally, we outline future directions in multimodal delivery, pathology-adapted design, standardized evaluation, and scalable manufacturing, which will be essential for transforming TDD from a permeability enhancement technology into a precision-regulated therapeutic platform.

PMID 42717625
阅读全文 →
PubMedCureus2026-09-10

Treating Intractable Nausea and Vomiting in Cerebellar and Medullary Stroke.

Bhatti Adil A, Schultz Peter P, Amin Shantanu S, Khalid Taimur T et al.

Cerebellar and medullary stroke can cause persistent nausea and vomiting that may be resistant to initial antiemetic monotherapy and interfere with oral intake and recovery. Evidence guiding management remains limited. We report a 48-year-old man with diabetes mellitus and acute-to-subacute infarcts involving the inferomedial right cerebellum and posterior right medulla who presented with 10 days of persistent nausea and vomiting accompanied by focal neurologic symptoms. Diabetic gastroparesis was considered, but abdominal imaging and gastric emptying scintigraphy did not support a contributory gastrointestinal cause. Ondansetron and metoclopramide provided only limited or temporary relief. Symptoms improved after sequential escalation to ondansetron, chlorpromazine, prochlorperazine, and amitriptyline; transdermal scopolamine was included in the discharge regimen. Nausea and vomiting were nearly resolved before discharge and fully resolved by three-month follow-up. Because multiple medications were introduced over a short interval and natural neurologic recovery may have contributed, the effect of any individual agent or combination cannot be determined. This case suggests that receptor-diverse pharmacotherapy may be considered when initial treatment fails while underscoring the need for further study of efficacy, safety, and medication sequencing.

PMID 42719464
阅读全文 →
PubMedFrontiers in endocrinology2026-09-10

Carbohydrate counting knowledge and its association with diabetes distress in patients with type 1 diabetes: a cross-sectional study from the United Arab Emirates.

Agha Adnan A, Rakha Sozan Yasser SY, Afandi Bachar B, Kalupahana Nishan Sudheera NS et al.

Carbohydrate counting is central to dietary self-management in patients with type 1 diabetes mellitus (T1DM). However, objective assessments of carbohydrate counting knowledge and its relationship with psychosocial outcomes are scarce in Gulf populations. This study assessed carbohydrate counting knowledge, diabetes distress, and hypoglycaemia awareness in patients with T1DM attending a tertiary diabetes centre in the United Arab Emirates. This was a cross-sectional study of 40 patients with T1DM (age ≥ 14 years, diabetes duration ≥ 12 months) attending the Tawam Hospital Diabetes Clinic, Al Ain, UAE. Carbohydrate counting knowledge was assessed using the Arabic version of the 43-item AdultCarbQuiz questionnaire. Diabetes distress was measured using the two-item Diabetes Distress Scale (DDS-2), and hypoglycaemia awareness was measured using the Gold score. Pearson's correlations, one-way analysis of variance (ANOVA) across knowledge quartiles, and partial correlations adjusted for HbA1c and Gold score were performed. The mean AdultCarbQuiz score was 26.2 ± 4.0 out of 43 (60.9%). Domain analysis revealed strong carbohydrate food recognition (domain mean 80.1% correct) but poor quantification skills (20-27.5% correct for portion estimation) and meal-level counting (2.5-15% correct). Diabetes distress was present in 37.5% of the participants, and impaired hypoglycaemia awareness was present in 20.0% of the participants. Knowledge of carbohydrate counting showed a moderate inverse correlation with diabetes distress (r = -0.468, 95% CI -0.68 to -0.18, p = 0.002), which strengthened further after adjusting for HbA1c and Gold score (partial r = -0.579, 95% CI -0.77 to -0.30, p < 0.001). In exploratory analyses, younger age (r = -0.404, p = 0.010) and shorter diabetes duration (r = -0.344, p = 0.030) were associated with higher knowledge scores. No association was observed between the knowledge scores and HbA1c levels (r = 0.179, p = 0.295). In this cross-sectional sample, carbohydrate counting knowledge was independently and inversely associated with diabetes distress, regardless of glycaemic control. Specific knowledge gaps in carbohydrate quantification and meal-level counting are actionable targets for educational intervention in this population. These findings highlight the value of addressing both nutritional knowledge and emotional well-being in T1DM management; whether improving carbohydrate-counting knowledge reduces distress requires longitudinal and interventional study.

PMID 42718806
阅读全文 →
PubMedDrugs in R&D2026-09-09

Study on the Pharmacokinetics and Pharmacodynamics of Transdermal Estradiol Gel Administered Repeatedly in Postmenopausal Women.

Sirviö Jouni J, Ahtola-Sätilä Tuula T, Kirjavainen Merja M, Rytilä Paula P

Transdermal administration of estrogen has established its positioning among hormone replacement therapies in menopause. In Divigel® (estradiol hemihydrate gel 0.1%), 17β-estradiol, a body-identical estrogen, is formulated to be absorbed through the skin. This study aimed to provide systematic data on the pharmacokinetics and pharmacodynamics of Divigel to further enable its use in individualized therapies. The study was conducted over a 14-day treatment period using three escalating doses (0.5 mg, 1.0 mg, and 1.5 mg) in ten postmenopausal women. A 3-day or 4-day follow-up period was conducted after each treatment period. Wash-out between the periods was at least 2 weeks. The serum levels of estradiol (E2) and its metabolite estrone (E1) were analyzed, and the therapeutically informative ratio of E2/E1 was calculated. In addition, the temporal course of the excretion of E1, E2, and estriol (E3) in urine was studied. Serum levels of gonadotropins, follicle-stimulating hormone and luteinizing hormone, were measured as pharmacodynamic biomarkers. Serum concentrations of E2 were proportional to dose, and profiles were dose dependent. A steady-state E2 concentration was achieved within 3-5 days of daily administration of 1.0-mg and 1.5-mg doses. After the first and last application, the serum E2/E1 ratio increased clearly above 1.0 within 2-12 hours post-dose, i.e., approximating premenopausal levels, whereas it returned and remained close to parity at steady state, which still is clearly above the measured baseline (menopausal) levels. The urine levels of E1 and E3 were comparable and much higher than E2 urine levels. After the last application on day 14, the average serum concentration values of E2 (calculated as area under the concentration-time curve from time 0 to 24 hours divided by the 24-hour application interval) were 12.4 ± 7.0, 29.7 ± 7.3, and 55.0 ± 33.1 pg/mL at 0.5-mg, 1.0-mg and 1.5-mg doses, respectively. Those fit into the clinically effective concentration range at the doses of 1.0 mg or 1.5 mg in all the subjects. Follicle-stimulating hormone levels were lower after application of Divigel at every dose compared with their pre-dosing baseline. Luteinizing hormone levels also decreased following E2 administration. Treatment was well tolerated, and no safety concerns or skin reactions were observed. Transdermal estradiol treatment with Divigel produced dose-proportional, clinically meaningful serum E2 levels and E2/E1 ratios in postmenopausal women. All administered doses also showed expected hormonal pharmacodynamic effects and were well tolerated. Not applicable in the USA and European Union for a pharmacokinetic study commenced in 1999.

PMID 42714801
阅读全文 →
PubMedArchives of suicide research : official journal of the International Academy for Suicide Research2026-09-09

Evaluating Problematic Social Media, Metacognitive Beliefs, and Cybervictimization in Depressed Adolescents with and without a History of Suicide Attempt.

Öztürk Masum M, Özkan Yekta Y, Ünal-Aydın Pınar P, Aydın Orkun O

Research has demonstrated the relationship between major depressive disorder (MDD) and cybervictimization, social media use, and dysfunctional metacognition in adolescents. Nevertheless, there is scarcity in adolescent studies focusing on the relationship between these factors and there is a gap in examining the role of these factors with a history of suicide attempt. For the purpose of this study; 76 MDD patients without a history of suicide attempt, 75 MDD patients with a history of suicide attempt, and 84 controls were recruited. Data for the study were obtained using self-report DSM-5 Level 2 Depression Scale, Child Age 11-17 (DDS-II), Social Media Disorder Scale (SMDS), Metacognitions Questionnaire for Children (MCQ-C) ve Revised Cyberbullying Inventory-II (RCBI-II) scales. Results demonstrated that problematic social media use, dysfunctional metacognitive beliefs, and cybervictimization were more prevalent in the MDD with a history of suicide attempt group. Furthermore, a binary logistic regression analysis identified the factors significantly associated with suicide attempts in MDD group. Accordingly, cybervictimization, and two factors of metacognitive beliefs including negative meta-worry and superstition, punishment and responsibility beliefs emerged as key determinants. These findings suggest that cybervictimization and metacognitive beliefs may be considered an important factor that clinicians should pay attention when monitoring suicidality and treating MDD among adolescents. While the cross-sectional design of this study limits causal inferences, these findings suggest that addressing dysfunctional metacognitive beliefs and cyber victimization may be an important component of the clinical management of adolescents with MDD who have a history of suicide attempts.

PMID 42714373
阅读全文 →
PubMedInternational journal of pharmaceutics2026-09-09

A liposome-in-hydrogel hybrid system for spatially targeted delivery and prolonged intradermal retention of vitamin K1 against EGFR inhibitor-induced skin toxicity.

Wang Tianying T, Zhang Xinyi X, Zhou Lingling L, Wen Kaichao K et al.

Epidermal growth factor receptor (EGFR) inhibitors frequently cause cutaneous toxicities that impair patients' quality of life and may compromise treatment adherence. Although topical vitamin K1 (VK1) has shown therapeutic potential, its clinical efficacy remains inconsistent, largely due to poor distribution within pharmacologically relevant skin compartments, particularly the viable epidermis and pilosebaceous units. To address this, we developed a VK1-loaded liposome‑in‑hydrogel (VK1-Lipo-Gel) capable of sustaining intradermal drug residence while minimizing systemic exposure. Compared with the commercial VK1 cream, VK1-Lipo-Gel markedly prolonged VK1 retention in the skin. VK1 remained detectable in the viable epidermis-dermis (VED) for up to 36 h, yielding a Cmax of 1.64 ± 0.10 μg/cm2 at 8 h and an AUC0-36h of 33.16 ± 1.70 μg·h/cm2. Notably, the formulation promoted preferential localization within the VED and pilosebaceous units, with plasma VK1 levels below the LLOQ. More importantly, VK1‑Lipo‑Gel did not compromise the antitumor efficacy of erlotinib. In an erlotinib-induced skin toxicity model, by restoring EGFR-ERK signaling, VK1-Lipo-Gel more effectively reinforced epidermal barrier function, attenuated inflammatory responses, and ameliorated follicle‑associated alterations. These results demonstrate that optimizing intradermal retention and compartment‑specific distribution, rather than simply increasing transdermal flux, is a superior strategy for managing EGFR inhibitor-induced cutaneous toxicity, and support the translational potential of liposome‑hydrogel hybrids for topical drug delivery.

PMID 42716152
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多transdermal DDS